About Orphagen
Orphagen is a Healthcare company based in San Diego (United States) founded in 2001. Specialty company focused on translational research, discovering new classes of small molecule drugs. The company has 7 employees. Orphagen offers products and services including OR-449, OR-812, and RORΞ². Its focus areas include Diversified Pharmaceuticals, Life Sciences, Life Sciences Platforms and Tools and Research Services. Its legal entity is ORPHAGEN PHARMACEUTICALS. Its competitors include Slingshot Bioscience, StemoniX and Signal Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2001, Orphagen operates as a preclinical-stage drug discovery and research services firm in San Diego, United States. Focus is placed on translational research targeting orphan nuclear receptors for conditions such as autoimmune diseases, Cushings syndrome, and retinal degeneration. Validated transcriptional and biochemical assays are provided on a contract basis for steroid hormone, metabolic, retinoid, and orphan receptors, with custom assay development available upon request.
- Headquarters San Diego, United States
- Employees 7
- SectorsHealthcare
- Website orphagen.com
- Legal Name Orphagen Pharmaceuticals
- Latest Funding Round$1.7M (USD), Grant
Dec 2024
- InvestorsHHS
& 2 more
- Employee Count7
Products & Services of Orphagen
Orphagen offers a comprehensive portfolio of products and services, including OR-449, OR-812, and RORβ.
Small molecule therapy for adrenal and squamous cancers
Targets nuclear receptors in cancer treatment
Small molecule for inflammatory diseases like ulcerative colitis
Funding Insights of Orphagen
- Total Rounds 17
- Last Round Grant β $1.7M
- First Round $1.17M
(Sep 2005)
- Investors Count 3
Latest 10 of 17 funding rounds of Orphagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $1.7M | Grant | β | β | |
| Sep 2024 | $1.08M | Grant | β | β | |
| Jul 2021 | $2M | Grant | β | β | |
| Aug 2019 | $1.81M | Grant | β | β | |
| Sep 2015 | $325,051 | Grant | β | β | |
| Sep 2014 | $223,229 | Grant | β | β | |
| Jun 2013 | $80,000 | Debt – Venture | β | β | |
| Jun 2013 | $447,635 | Grant | β | β | |
| Aug 2012 | $250,507 | Grant | β | β | |
| Sep 2011 | $220,839 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Orphagen
Orphagen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Institute of Diabetes and Digestive and Kidney Diseases and Vencore Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| vencorecapital.com | ||||
Research and health information on diabetes and kidney diseases are provided by NIDDK. | 1950 | niddk.nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Orphagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orphagen
7 people are tracked at Orphagen (4 in leadership, 3 in board & advisors); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Neil Raheja | Director of Chemistry | Leadership |
Paul Crowe | VP, Drug Discovery | Leadership |
Scott Thacher | CEO & Board Member | Leadership |
Jukka Muhonen | Vice President, Business Development | Leadership |
Casey Weaver | Scientific Advisor | Board & advisors |
Richard Auchus | Scientific Advisor | Board & advisors |
Len Post | Board Member | Board & advisors |
Complete people profiles for Orphagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orphagen
3 dated milestones of Orphagen across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Orphagen is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $1.7M.
Competitors of Orphagen
Orphagen has 3 listed competitors in our database, 3 of them funded. They include Slingshot Bioscience, StemoniX and Signal Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| slingshotbio.com | 2012 | Berkeley, United States | $46.38M | 46 | Next-generation synthetic cells are developed for diagnostics and therapeutics. | |
| stemonix.com | 2014 | San Diego, United States | $33.7M | Developing a commercial scale printer for the high-volume growth and differentiation of stem cells and stem cell products. | ||
| signalpharm.com | 1993 | San Diego, United States | $12M | Small molecule drugs regulating disease-associated genes are developed. |
Detailed competitors of Orphagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Orphagen
The website of Orphagen (orphagen.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 1529.9% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Orphagen (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orphagen
Complete news archive for Orphagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphagen
Orphagen was founded in 2001 and raised its 1st funding round 4 years after it was founded.
Orphagen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Orphagen has 7 employees.
Founded in 2001, Orphagen operates as a preclinical-stage drug discovery and research services firm in San Diego, United States. Focus is placed on translational research targeting orphan nuclear receptors for conditions such as autoimmune diseases, Cushings syndrome, and retinal degeneration. Validated transcriptional and biochemical assays are provided on a contract basis for steroid hormone, metabolic, retinoid, and orphan receptors, with custom assay development available upon request.
Orphagen's top competitors include Slingshot Bioscience, StemoniX and Signal Pharmaceuticals.
Orphagen offers OR-449, OR-812, and RORΞ².
Orphagen has 3 investors. Key investors include HHS, National Institute of Diabetes and Digestive and Kidney Diseases, and Vencore Capital.
Orphagen operates through Orphagen Pharmaceuticals.